TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 years with informed consent~* Diagnosis of rheumatoid arthritis (according to 2010 ACR/EULAR classification criteria)~* Disease duration \> 6 weeks~* Swollen joint (SJC)≥4 and tender joint count(TJC)≥4~* ESR \>28 mm/hr or C-reactive protein \> 1.5 ULN~* Positive RF or anti-CCP antibody on screening~* Class I, II or III of the ACR 1991 Revised Criteria for Global Functional Status in RA~* No evidence of active or latent or inadequately treated Mycobacterium tuberculosis infection~Exclusion Criteria:~* Pregnant, lactating or further fertility requirements~* Previously received any biologic agents.~* Recently (\<12 weeks) received methotrexate, leflunomide, salazosulfapyridine, azathioprine, cyclosporine, mycophenolate mofetil or Tripterygium Wilfordii.~* Active or chronic infection, including HIV, HCV, HBV, tuberculosis.~* History of any other rheumatic autoimmune disease~* History of any lymphoproliferative disorder~* Malignancy or history of malignancy.~* Abnormal laboratory tests, including: Hemoglobin \<8.5 g/dL, White blood cell count \<3.5 x 109/L, Platelet count \<100 x 109/L, AST/ALT \>1.5 ULN, and serum creatine \> 1.5 mg/dL.~* Severe, progressive, or uncontrolled cardiac, pulmonary, renal, hepatic, gastrointestinal, hematologic, metabolic, endocrine or neurologic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MTX (Type: PLACEBO_COMPARATOR): Treated with oral methotrexate and two placebos.
- Tripterygium Wilfordii (Type: PLACEBO_COMPARATOR): Treated with oral Tripterygium Wilfordii and two placebos.
- Yisaipu + MTX (Type: ACTIVE_COMPARATOR): Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
- Yisaipu + Tripterygium Wilfordii (Type: EXPERIMENTAL): Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Seroma Reduction After Mastectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Older than 18 years~* Female sex~* Indication for mastectomy or modified radical mastectomy~Exclusion Criteria:~* Patients undergoing breast conserving therapy~* Patients undergoing direct breast reconstruction~* Unable to comprehend implications and extent of study and sign for informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- conventional wound closure (Type: ACTIVE_COMPARATOR): The skin flaps will not undergo further treatment in this group.
- flap fixation with vicryl sutures (Type: EXPERIMENTAL): The skin flaps will be sutured on to the pectoral muscle after having performed the mastectomy.
- Artiss tissue glue (Type: EXPERIMENTAL): ARTISS tissue glue will be applied to the skin flaps after mastectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Pathologically confirmed posterior fossa medulloblastoma (CCG diagnosis code 2041) Localized disease required, i.e.: No more than 1.5 square centimeters of residual tumor on postoperative contrast-enhanced CT or MRI (preferably within 72 hours but no more than 14 days after surgery) No evidence of metastatic disease on pre- and postoperative MRI of spine (with dye enhancement) and lumbar cerebrospinal fluid (CSF) cytology within 3 days prior to surgery Cytologic analysis of ventricular CSF allowed only if medical contraindication to lumbar puncture and with approval of study chairperson Brain stem involvement eligible~PATIENT CHARACTERISTICS: Age: 3 to 21 at diagnosis Performance status: Not specified Hematopoietic: ANC greater than 1,500/mm3 Platelet count greater than 100,000/mm3 Hemoglobin greater than 10 g/dL Hepatic: Bilirubin less than 1.5 mg/dL ALT less than 1.5 times normal Renal: Nuclear glomerular filtration rate or creatinine clearance greater than 70 mL/min per 1.73 square meters~PRIOR CONCURRENT THERAPY: No prior radiotherapy or chemotherapy (other than corticosteroids) No more than 31 days since definitive surgery

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- Regimen A (Type: EXPERIMENTAL): Following surgery, craniospinal irradiation followed by a boost to the primary tumor. Beginning within 1 week after initiation of radiotherapy, patients receive vincristine sulfate weekly for 8 doses. Beginning 6 weeks after the completion of radiotherapy, patients receive adjuvant lomustine/vincristine sulfate/cisplatin every 6 weeks for a total of 8 courses.
- Regimen B (Type: EXPERIMENTAL): Following surgery, craniospinal irradiation plus vincristine sulfate, followed by adjuvant cyclophosphamide/vincristine sulfate/cisplatin every 6 weeks for a total of 8 courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women with recurrent surface immunoglobulin positive B cell non-Hodgkin's lymphoma (NHL) according to WHO classification (including, but not limited to, CLL/SLL, Waldenström's macroglobulinemia \[WM\], mantle cell lymphoma \[MCL\], and diffuse large B cell lymphoma \[DLBCL) who have met requirements for roll over from their parent protocol and want to continue study drug.~* Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 3 days of the first dose of study drug and agree to use dual methods of contraception during the study and for 1 month following the last dose with study drug. Post menopausal females (\>45 years old and without menses for \>1 year) and surgically sterilized females are exempt from this criterion.~* Male subjects must use an effective barrier method of contraception during the study and for 3 months following the last dose if sexually active with a female of childbearing potential.~* Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty~* Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).~Exclusion Criteria:~* A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of PCI-32765 PO, or put the study outcomes at undue risk~* Known history of Human Immunodeficiency Virus (HIV) or active infection with Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV) or any uncontrolled active systemic infection.~* Lactating or pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCI-32765 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 7 years old or younger with amblyopia due to strabismus or anisometropia~* Visual acuity in the amblyopic eye must be between 20/40 and 20/100~* Visual acuity in the sound eye or 20/40 or better~* At least 3 lines of acuity difference between the two eyes~Exclusion Criteria:~* More than two months of amblyopia therapy in the past two years~* Myopia (more than -0.50 D)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Patching (Type: ACTIVE_COMPARATOR): None
- Atropine (Type: ACTIVE_COMPARATOR): Atropine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults greater than or equal to (≥) 18 years of age~* Histologically or cytologically documented inoperable, locally advanced, metastatic, or recurrent NSCLC~* Previous treatment with no more than 2 prior chemotherapy regimens~Exclusion Criteria:~* Previous systemic anti-cancer therapy with human epidermal growth factor receptor 1 (HER1)/epidermal growth factor receptor (EGFR) inhibitors~* Inability to take oral medication~* Any other malignancies within 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Erlotinib will be given as a single agent in this expanded access program (EAP) to participants with inoperable, locally advanced, recurrent, or metastatic NSCLC. Treatment will continue until unacceptable toxicity, disease progression, or withdrawal for any other reason.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Brexpiprazole in Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients, or inpatients at the time of informed consent whose treatment status can be successfully shifted to outpatient status before enrollment in the antidepressant treatment period~* Male and female patients ≥ 20 to \< 65 years of age (at the time of informed consent)~* Patients who have a level of comprehension sufficient to allow them to give written informed consent to all of the observation/examination/evaluation items specified in the protocol, and who can understand the contents of the trial~* Patients with a DSM-5 classification-based diagnosis of major depressive disorder, single episode or major depressive disorder, recurrent episode, and whose current episode has persisted for at least 8 weeks~Exclusion Criteria:~* Women who are pregnant or breastfeeding or who have positive pregnancy test (urine) results at screening~* Sexually active male subjects or sexually active female subjects of childbearing potential, who will not agree to practice 2 different methods of birth control or to remain abstinent during the trial and for 30 days after the final~IMP administration. For birth control, 2 of the following methods must be used:~vasectomy, tubal ligation, vaginal diaphragm, intra-uterine contraceptive device (IUD), oral contraceptives, or condom with spermicide.~* Patients with a treatment history showing that all antidepressants (including those not used for the current major depressive episode) cannot be tolerated~* Patients with a history of electroconvulsive therapy~* Patients with a diagnosis of any of the following diseases according to DSM-5~  1. Neurocognitive disorders~ 2. Schizophrenia spectrum and other psychotic disorders~ 3. Bipolar and related disorders~ 4. Feeding and eating disorders~ 5. Obsessive-compulsive disorder~ 6. Panic disorder~ 7. Posttraumatic stress disorder

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole 1mg (Type: EXPERIMENTAL): Tablets, Oral, 1mg once daily, 14 weeks Other Name: REXULTI
- Brexpiprazole 2mg (Type: EXPERIMENTAL): Tablets, Oral, 2 mg once daily, 14 weeks Other Name: REXULTI
- Placebo (Type: PLACEBO_COMPARATOR): Tablets, Oral, once daily, 14 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endometriosis and the Appendix - Incidence and Pathologic Analysis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English Speaking~* Women age 18-51 years of age~* Chronic pelvic pain and/or diagnosis of endometriosis~* Appendix removed at time of laparoscopy for treatment of endometriosis and/or pelvic pain~Exclusion Criteria:~* Non-English speaking~* Previous appendectomy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 51 Years
- Healthy Volunteers: f

Study Arms:
- Standard analysis (Type: OTHER): Standard pathological analysis currently used.
- Modified Pathologic Analysis (Type: OTHER): After undergoing standard pathologic analysis, each specimen will then undergo the modified pathologic analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is scheduled for a partial small/large bowel resection of primary anastomosis or total abdominal hysterectomy (simple or radical) via laparotomy~* Subject is scheduled to receive primary postoperative pain management with intravenous (i.v.) patient-controlled analgesia (PCA) opioids~Exclusion Criteria:~* Subject is scheduled for a total colectomy, colostomy, ileostomy~* Subject has complete bowel obstruction~* Subject is currently taking opioid analgesics or has taken opioid analgesics within 4 weeks prior to surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multiple Ascending Dose (MDX1105-01)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1~* The malignancies include relapsed/refractory renal cell carcinoma, non-small cell lung cancer, colorectal adenocarcinoma, malignant melanoma, advanced/metastatic epithelial ovarian cancer, gastric cancer, pancreatic cancer and breastcancer~* Must have measurable disease~Exclusion Criteria:~* Prior therapy with an anti-PD 1, anti-PDL 1, or anti-Cytotoxic T-Lymphocyte Antigen 4 antibody (or any other agents that target T-cell co-stimulation)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anti-PDL-1 antibody (Arm 1) (Type: EXPERIMENTAL): BMS-936559 (MDX-1105)
- Anti-PDL-1 antibody (Arm 2) (Type: EXPERIMENTAL): BMS-936559 (MDX-1105)
- Anti-PDL-1 antibody (Arm 3) (Type: EXPERIMENTAL): BMS-936559 (MDX-1105)
- Anti-PDL-1 antibody (Arm 4) (Type: EXPERIMENTAL): BMS-936559 (MDX-1105)
- Anti-PDL-1 antibody (Arm 5) (Type: EXPERIMENTAL): BMS-936559 (MDX-1105)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient aged ≥55 years old~* With newly diagnosed ALL without prior treatment~* Capable to receive polychemotherapy (World Health Organization (WHO) performance status ≤2)~* With or without meningeal disease~* Having signed an Informed Consent Form~* Subscribed to social security insurance~Exclusion Criteria:~* ALL translocation(9;22) and/or BCR-ABL (Breakpoint Cluster Region-Abelson) positive~* Performance status incompatible with chemotherapy treatment (WHO score \>2)~* Patient presenting with a general or visceral contraindication to intensive treatment including :~  * Cardiac insufficiency defined as Left Ventricular Ejection Fraction \<50% of the theoretical value~ * Plasma creatinine concentration 2 times greater than the upper limit of laboratory ranges, except if related to ALL~ * Aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) levels 5 times greater than the upper limit of laboratory ranges, except if related to ALL~ * Patient with another evolutive cancer other than ALL~ * Severe evolutive infection, or Human Immunodeficiency Virus (HIV) seropositive or, active hepatitis related to B or C viral infection~* Prior treatment with L-asparaginase (irrespective of the form)~* History of grade 3 transfusional incident (life threatening)~* Patient presenting rare and/or dangerous anti-erythrocyte antibodies thus leading to the unavailability of phenotype compatible Red Blood Cells Concentrate~* Patient included in another clinical trial during the last 4 weeks

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GRASPA 50 IU/kg (Type: EXPERIMENTAL): Each patient will receive GRASPA 50 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase.
- GRASPA 100 IU/kg (Type: EXPERIMENTAL): Each patient will receive GRASPA 100 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
- GRASPA 150 IU/kg (Type: EXPERIMENTAL): Each patient will receive GRASPA 150 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Empirically-Based Couple Interventions on the Web: Serving the Underserved

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently in a heterosexual relationship~* Currently married, engaged, or cohabiting for at least 6 months~* At least one partner scoring in distressed range of relationship satisfaction (or both partners \> 0.5 SD of population mean of distress).~* Living in the United States~* Both partners ages 21-64 (inclusive)~Exclusion Criteria:~* Severe Intimate Partner Violence in last 3 months~* Moderate to severe suicidal ideation in last 3 months~* Concrete plans to divorce~* Ongoing affair~* Ongoing couple therapy (or refusal to seek couple therapy for 3 months)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- OurRelationship (Type: EXPERIMENTAL): Online Intervention
- Waitlist Control (Type: NO_INTERVENTION): 2 month waiting period before couples can receive intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete